The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Female

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Female.
Connection Strength

3.886
  1. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2349646.
    View in: PubMed
    Score: 0.045
  2. Unawareness of breast cancer family history among African women. Pan Afr Med J. 2023; 45:188.
    View in: PubMed
    Score: 0.045
  3. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
    View in: PubMed
    Score: 0.044
  4. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
    View in: PubMed
    Score: 0.043
  5. Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing. JCO Glob Oncol. 2023 02; 9:e2100140.
    View in: PubMed
    Score: 0.043
  6. An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer. Hum Mol Genet. 2023 01 01; 32(1):139-150.
    View in: PubMed
    Score: 0.043
  7. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PLoS One. 2022; 17(6):e0268693.
    View in: PubMed
    Score: 0.041
  8. Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Glob Oncol. 2022 05; 8:e2200017.
    View in: PubMed
    Score: 0.041
  9. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun; 193(2):485-494.
    View in: PubMed
    Score: 0.040
  10. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.039
  11. Evaluating the Effect of Medicaid Expansion on Black/White Breast Cancer Mortality Disparities: A Difference-in-Difference Analysis. JCO Glob Oncol. 2020 07; 6:1178-1183.
    View in: PubMed
    Score: 0.036
  12. Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complement Med Ther. 2020 Mar 20; 20(1):93.
    View in: PubMed
    Score: 0.035
  13. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
    View in: PubMed
    Score: 0.034
  14. Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling. Cancer Imaging. 2019 Jul 15; 19(1):48.
    View in: PubMed
    Score: 0.033
  15. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J Cancer. 2019 12 15; 145(12):3321-3333.
    View in: PubMed
    Score: 0.033
  16. The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. J Clin Oncol. 2019 08 20; 37(24):2177-2178.
    View in: PubMed
    Score: 0.033
  17. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
    View in: PubMed
    Score: 0.033
  18. LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Sci Rep. 2018 10 22; 8(1):15572.
    View in: PubMed
    Score: 0.032
  19. Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018 10; 17(4):471-483.
    View in: PubMed
    Score: 0.032
  20. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
    View in: PubMed
    Score: 0.032
  21. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.032
  22. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
    View in: PubMed
    Score: 0.031
  23. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. J Glob Oncol. 2018 07; 4:1-8.
    View in: PubMed
    Score: 0.031
  24. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
    View in: PubMed
    Score: 0.031
  25. Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. J Genet Couns. 2018 08; 27(4):863-873.
    View in: PubMed
    Score: 0.030
  26. Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS One. 2016; 11(11):e0165559.
    View in: PubMed
    Score: 0.028
  27. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
    View in: PubMed
    Score: 0.027
  28. Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer. 2016 Jun; 16(3):e61-3.
    View in: PubMed
    Score: 0.026
  29. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015 May-Jun; 65(3):221-38.
    View in: PubMed
    Score: 0.025
  30. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
    View in: PubMed
    Score: 0.025
  31. ß-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016 May; 55(5):431-9.
    View in: PubMed
    Score: 0.025
  32. Race, ethnicity, and the diagnosis of breast cancer. JAMA. 2015 Jan 13; 313(2):141-2.
    View in: PubMed
    Score: 0.025
  33. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health. 2015; 10(3):331-44.
    View in: PubMed
    Score: 0.024
  34. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.024
  35. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.024
  36. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
    View in: PubMed
    Score: 0.024
  37. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
    View in: PubMed
    Score: 0.022
  38. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
    View in: PubMed
    Score: 0.022
  39. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013 Jul; 43(1):5-12.
    View in: PubMed
    Score: 0.022
  40. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
    View in: PubMed
    Score: 0.022
  41. Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health. 2013 Jan 16; 13:40.
    View in: PubMed
    Score: 0.021
  42. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
    View in: PubMed
    Score: 0.021
  43. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012 Sep; 18(5):436-42.
    View in: PubMed
    Score: 0.021
  44. Hidden dangers: a cryptic exon disrupts BRCA2 mRNA. Clin Cancer Res. 2012 Sep 15; 18(18):4865-7.
    View in: PubMed
    Score: 0.021
  45. Protective effect of longstanding lactation and reproductive factors: a case-control study in North Tanzania. Breast Cancer Res Treat. 2012 Aug; 134(3):1349-51.
    View in: PubMed
    Score: 0.021
  46. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
    View in: PubMed
    Score: 0.021
  47. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
    View in: PubMed
    Score: 0.021
  48. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
    View in: PubMed
    Score: 0.020
  49. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
    View in: PubMed
    Score: 0.020
  50. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
    View in: PubMed
    Score: 0.020
  51. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
    View in: PubMed
    Score: 0.020
  52. Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst. 2011 Oct 19; 103(20):1486-8.
    View in: PubMed
    Score: 0.020
  53. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.019
  54. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer. 2011 Jun 13; 11:246.
    View in: PubMed
    Score: 0.019
  55. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol. 2011 Apr; 38(2):263-73.
    View in: PubMed
    Score: 0.019
  56. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol. 2011 May 01; 29(13):1652-4.
    View in: PubMed
    Score: 0.019
  57. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011 Mar 01; 117(5):907-15.
    View in: PubMed
    Score: 0.018
  58. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
    View in: PubMed
    Score: 0.018
  59. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
    View in: PubMed
    Score: 0.018
  60. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.018
  61. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
    View in: PubMed
    Score: 0.017
  62. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 2010 Jan-Feb; 16(1):23-32.
    View in: PubMed
    Score: 0.017
  63. Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
    View in: PubMed
    Score: 0.017
  64. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.017
  65. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 2010 Apr; 120(3):593-601.
    View in: PubMed
    Score: 0.017
  66. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.016
  67. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15; 14(24):7988-99.
    View in: PubMed
    Score: 0.016
  68. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.016
  69. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.016
  70. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Aff (Millwood). 2008 Mar-Apr; 27(2):339-49.
    View in: PubMed
    Score: 0.015
  71. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.015
  72. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
    View in: PubMed
    Score: 0.015
  73. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
    View in: PubMed
    Score: 0.015
  74. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007 Dec; 7(12):937-48.
    View in: PubMed
    Score: 0.015
  75. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20.
    View in: PubMed
    Score: 0.015
  76. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
    View in: PubMed
    Score: 0.015
  77. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007 Sep; 8(3):255-67.
    View in: PubMed
    Score: 0.014
  78. UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos. 2007 Aug; 35(8):1254-61.
    View in: PubMed
    Score: 0.014
  79. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.014
  80. Using genetic analysis to individualize preventive measures for breast and ovarian cancers. Nat Clin Pract Oncol. 2006 Apr; 3(4):182-3.
    View in: PubMed
    Score: 0.013
  81. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
    View in: PubMed
    Score: 0.013
  82. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
    View in: PubMed
    Score: 0.013
  83. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.013
  84. Racial and ethnic disparities in breast cancer: a multilevel perspective. Med Clin North Am. 2005 Jul; 89(4):753-70.
    View in: PubMed
    Score: 0.013
  85. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. J Med Genet. 2005 Mar; 42(3):276-81.
    View in: PubMed
    Score: 0.012
  86. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.012
  87. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes Control. 2024 May; 35(5):787-798.
    View in: PubMed
    Score: 0.011
  88. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004 Jan-Feb; 10 Suppl 1:S5-9.
    View in: PubMed
    Score: 0.011
  89. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.011
  90. Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
    View in: PubMed
    Score: 0.011
  91. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
    View in: PubMed
    Score: 0.011
  92. Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2024 Mar; 30(3):651-663.
    View in: PubMed
    Score: 0.011
  93. Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations. JCO Glob Oncol. 2023 Sep; 9:e2300154.
    View in: PubMed
    Score: 0.011
  94. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003 Sep 01; 21(17):3191-3.
    View in: PubMed
    Score: 0.011
  95. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
    View in: PubMed
    Score: 0.011
  96. Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003 Jul; 13(6):455-61.
    View in: PubMed
    Score: 0.011
  97. A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes. Am J Hum Genet. 2023 06 01; 110(6):950-962.
    View in: PubMed
    Score: 0.011
  98. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003 May; 3(5):417-20.
    View in: PubMed
    Score: 0.011
  99. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.011
  100. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 2003 Mar; 22(1):47-53.
    View in: PubMed
    Score: 0.011
  101. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
    View in: PubMed
    Score: 0.011
  102. A metabolome-wide case-control study of african american breast cancer patients. BMC Cancer. 2023 Feb 23; 23(1):183.
    View in: PubMed
    Score: 0.011
  103. The optimization of postoperative radiotherapy in de novo stage IV breast cancer: evidence from real-world data to personalize treatment decisions. Sci Rep. 2023 02 18; 13(1):2880.
    View in: PubMed
    Score: 0.011
  104. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med. 2023 01 26; 15(1):7.
    View in: PubMed
    Score: 0.011
  105. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
    View in: PubMed
    Score: 0.011
  106. Breast cancer genetics in African Americans. Cancer. 2003 Jan 01; 97(1 Suppl):236-45.
    View in: PubMed
    Score: 0.011
  107. Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. Integr Cancer Ther. 2023 Jan-Dec; 22:15347354231185122.
    View in: PubMed
    Score: 0.011
  108. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
    View in: PubMed
    Score: 0.011
  109. Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Hum Mol Genet. 2022 09 10; 31(18):3133-3143.
    View in: PubMed
    Score: 0.010
  110. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet. 2002 Sep; 71(3):625-31.
    View in: PubMed
    Score: 0.010
  111. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1351-1358.
    View in: PubMed
    Score: 0.010
  112. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
    View in: PubMed
    Score: 0.010
  113. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022 03 09; 12(1):4190.
    View in: PubMed
    Score: 0.010
  114. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
    View in: PubMed
    Score: 0.010
  115. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
    View in: PubMed
    Score: 0.010
  116. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
    View in: PubMed
    Score: 0.010
  117. Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. J Epidemiol Community Health. 2022 04; 76(4):411-417.
    View in: PubMed
    Score: 0.010
  118. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
    View in: PubMed
    Score: 0.010
  119. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. J Natl Cancer Inst. 2021 09 04; 113(9):1168-1176.
    View in: PubMed
    Score: 0.010
  120. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
    View in: PubMed
    Score: 0.010
  121. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
    View in: PubMed
    Score: 0.010
  122. Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nat Commun. 2021 07 07; 12(1):4198.
    View in: PubMed
    Score: 0.010
  123. Cancer genetics in oncology practice. Ann Oncol. 2001 Jul; 12(7):895-908.
    View in: PubMed
    Score: 0.010
  124. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Jun 28; 344(26):2028-9.
    View in: PubMed
    Score: 0.010
  125. Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. Am J Hum Genet. 2021 04 01; 108(4):564-582.
    View in: PubMed
    Score: 0.009
  126. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
    View in: PubMed
    Score: 0.009
  127. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.009
  128. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.009
  129. A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol. 2001 Feb; 80(2):121-3.
    View in: PubMed
    Score: 0.009
  130. The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Res. 2021 03 15; 81(6):1540-1551.
    View in: PubMed
    Score: 0.009
  131. Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Phys Med. 2021 Jan; 81:31-39.
    View in: PubMed
    Score: 0.009
  132. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849.
    View in: PubMed
    Score: 0.009
  133. p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nat Commun. 2020 10 06; 11(1):5007.
    View in: PubMed
    Score: 0.009
  134. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
    View in: PubMed
    Score: 0.009
  135. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
    View in: PubMed
    Score: 0.009
  136. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
    View in: PubMed
    Score: 0.009
  137. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
    View in: PubMed
    Score: 0.009
  138. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
    View in: PubMed
    Score: 0.009
  139. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
    View in: PubMed
    Score: 0.009
  140. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. 2020 09 01; 126(17):4013-4022.
    View in: PubMed
    Score: 0.009
  141. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
    View in: PubMed
    Score: 0.009
  142. Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genet Med. 2020 08; 22(8):1401-1406.
    View in: PubMed
    Score: 0.009
  143. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.009
  144. Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? J Racial Ethn Health Disparities. 2020 06; 7(3):577-583.
    View in: PubMed
    Score: 0.009
  145. Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys. 2000 Jan; 27(1):4-12.
    View in: PubMed
    Score: 0.009
  146. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.009
  147. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
    View in: PubMed
    Score: 0.009
  148. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
    View in: PubMed
    Score: 0.009
  149. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
    View in: PubMed
    Score: 0.008
  150. Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
    View in: PubMed
    Score: 0.008
  151. Two truncating variants in FANCC and breast cancer risk. Sci Rep. 2019 08 29; 9(1):12524.
    View in: PubMed
    Score: 0.008
  152. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.008
  153. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
    View in: PubMed
    Score: 0.008
  154. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians. Pharmacogenet Genomics. 2019 07; 29(5):106-113.
    View in: PubMed
    Score: 0.008
  155. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.008
  156. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019 04 15; 10(1):1741.
    View in: PubMed
    Score: 0.008
  157. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.008
  158. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289.
    View in: PubMed
    Score: 0.008
  159. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
    View in: PubMed
    Score: 0.008
  160. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
    View in: PubMed
    Score: 0.008
  161. Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. J Cancer Educ. 2019 02; 34(1):50-55.
    View in: PubMed
    Score: 0.008
  162. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.008
  163. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
    View in: PubMed
    Score: 0.008
  164. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
    View in: PubMed
    Score: 0.008
  165. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
    View in: PubMed
    Score: 0.008
  166. HIF-2a promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018 Oct 19; 37(1):256.
    View in: PubMed
    Score: 0.008
  167. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018 10 16; 9(1):4181.
    View in: PubMed
    Score: 0.008
  168. A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria. BMC Womens Health. 2018 09 19; 18(1):152.
    View in: PubMed
    Score: 0.008
  169. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst. 2018 09 01; 110(9):985-993.
    View in: PubMed
    Score: 0.008
  170. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.008
  171. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
    View in: PubMed
    Score: 0.008
  172. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 11; 27(11):1364-1370.
    View in: PubMed
    Score: 0.008
  173. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018 07; 50(7):968-978.
    View in: PubMed
    Score: 0.008
  174. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Mol Carcinog. 2018 10; 57(10):1311-1318.
    View in: PubMed
    Score: 0.008
  175. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
    View in: PubMed
    Score: 0.008
  176. Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev. 2018 06; 27(6):636-643.
    View in: PubMed
    Score: 0.008
  177. A meta-analysis approach with filtering for identifying gene-level gene-environment interactions. Genet Epidemiol. 2018 07; 42(5):434-446.
    View in: PubMed
    Score: 0.008
  178. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
    View in: PubMed
    Score: 0.008
  179. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018 02 01; 110(2).
    View in: PubMed
    Score: 0.008
  180. Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Mol Cancer Res. 2018 03; 16(3):461-469.
    View in: PubMed
    Score: 0.008
  181. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
    View in: PubMed
    Score: 0.008
  182. Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiol Biomarkers Prev. 2018 01; 27(1):116-118.
    View in: PubMed
    Score: 0.008
  183. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
    View in: PubMed
    Score: 0.007
  184. Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. Sci Total Environ. 2018 Apr 01; 619-620:212-220.
    View in: PubMed
    Score: 0.007
  185. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
    View in: PubMed
    Score: 0.007
  186. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94.
    View in: PubMed
    Score: 0.007
  187. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genet. 2017 Sep; 13(9):e1006727.
    View in: PubMed
    Score: 0.007
  188. Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
    View in: PubMed
    Score: 0.007
  189. Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium. Carcinogenesis. 2017 08 01; 38(8):789-796.
    View in: PubMed
    Score: 0.007
  190. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
    View in: PubMed
    Score: 0.007
  191. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.007
  192. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
    View in: PubMed
    Score: 0.007
  193. The Human Genome Project and breast cancer. Womens Health Issues. 1997 Jul-Aug; 7(4):209-14.
    View in: PubMed
    Score: 0.007
  194. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.007
  195. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Sci Total Environ. 2017 Dec 01; 599-600:2175-2181.
    View in: PubMed
    Score: 0.007
  196. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
    View in: PubMed
    Score: 0.007
  197. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1016-1026.
    View in: PubMed
    Score: 0.007
  198. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.007
  199. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.007
  200. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.007
  201. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112.
    View in: PubMed
    Score: 0.007
  202. Genetics in clinical cancer care--the future is now. N Engl J Med. 1996 Nov 07; 335(19):1455-6.
    View in: PubMed
    Score: 0.007
  203. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 11 01; 25(21):4835-4846.
    View in: PubMed
    Score: 0.007
  204. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
    View in: PubMed
    Score: 0.007
  205. A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. Nat Commun. 2016 10 11; 7:12522.
    View in: PubMed
    Score: 0.007
  206. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
    View in: PubMed
    Score: 0.007
  207. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Res Treat. 2016 11; 160(1):121-129.
    View in: PubMed
    Score: 0.007
  208. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
    View in: PubMed
    Score: 0.007
  209. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
    View in: PubMed
    Score: 0.007
  210. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.007
  211. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
    View in: PubMed
    Score: 0.007
  212. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
    View in: PubMed
    Score: 0.007
  213. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016 04 27; 7:11375.
    View in: PubMed
    Score: 0.007
  214. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. J Med Genet. 2016 08; 53(8):548-58.
    View in: PubMed
    Score: 0.007
  215. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.007
  216. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.007
  217. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.007
  218. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Apr; 48(4):374-86.
    View in: PubMed
    Score: 0.007
  219. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.007
  220. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):231-8.
    View in: PubMed
    Score: 0.007
  221. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One. 2016; 11(1):e0147145.
    View in: PubMed
    Score: 0.007
  222. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.007
  223. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.006
  224. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. PLoS One. 2015; 10(11):e0142224.
    View in: PubMed
    Score: 0.006
  225. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
    View in: PubMed
    Score: 0.006
  226. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View in: PubMed
    Score: 0.006
  227. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.006
  228. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 05; 141(2):386-401.
    View in: PubMed
    Score: 0.006
  229. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25; 17:61.
    View in: PubMed
    Score: 0.006
  230. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.006
  231. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
    View in: PubMed
    Score: 0.006
  232. ß-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10(2):e0117097.
    View in: PubMed
    Score: 0.006
  233. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
    View in: PubMed
    Score: 0.006
  234. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8.
    View in: PubMed
    Score: 0.006
  235. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.006
  236. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
    View in: PubMed
    Score: 0.006
  237. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.006
  238. National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
    View in: PubMed
    Score: 0.006
  239. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res. 2014 Dec 15; 74(24):7406-17.
    View in: PubMed
    Score: 0.006
  240. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
    View in: PubMed
    Score: 0.006
  241. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.006
  242. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. PLoS One. 2014; 9(9):e106908.
    View in: PubMed
    Score: 0.006
  243. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
    View in: PubMed
    Score: 0.006
  244. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
    View in: PubMed
    Score: 0.006
  245. A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014 Oct 15; 23(20):5518-26.
    View in: PubMed
    Score: 0.006
  246. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.006
  247. Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers. Med Phys. 2014 Mar; 41(3):031917.
    View in: PubMed
    Score: 0.006
  248. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol. 2013 Nov; 201(5):1155-63.
    View in: PubMed
    Score: 0.006
  249. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013 Nov; 142(1):177-85.
    View in: PubMed
    Score: 0.006
  250. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.006
  251. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis. 2014 Jan; 31(1):33-45.
    View in: PubMed
    Score: 0.006
  252. Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol. 2013 Oct; 33(19):3951-61.
    View in: PubMed
    Score: 0.006
  253. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol. 2013 Sep; 23(9):551-7.
    View in: PubMed
    Score: 0.006
  254. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
    View in: PubMed
    Score: 0.006
  255. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.005
  256. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.005
  257. Relationship between household air pollution from biomass smoke exposure, and pulmonary dysfunction, oxidant-antioxidant imbalance and systemic inflammation in rural women and children in Nigeria. Glob J Health Sci. 2013 Mar 18; 5(4):28-38.
    View in: PubMed
    Score: 0.005
  258. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
    View in: PubMed
    Score: 0.005
  259. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
    View in: PubMed
    Score: 0.005
  260. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
    View in: PubMed
    Score: 0.005
  261. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun. 2013; 4:1449.
    View in: PubMed
    Score: 0.005
  262. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82.
    View in: PubMed
    Score: 0.005
  263. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.005
  264. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.005
  265. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
    View in: PubMed
    Score: 0.005
  266. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
    View in: PubMed
    Score: 0.005
  267. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
    View in: PubMed
    Score: 0.005
  268. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
    View in: PubMed
    Score: 0.005
  269. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
    View in: PubMed
    Score: 0.005
  270. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.005
  271. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
    View in: PubMed
    Score: 0.005
  272. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.005
  273. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog. 2012 Oct; 51 Suppl 1:E83-93.
    View in: PubMed
    Score: 0.005
  274. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View in: PubMed
    Score: 0.005
  275. Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5.
    View in: PubMed
    Score: 0.005
  276. Clinical implications of ERß methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012 Sep; 29(3):1569-75.
    View in: PubMed
    Score: 0.005
  277. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012 Jun; 133(3):865-80.
    View in: PubMed
    Score: 0.005
  278. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011; 13(6):R110.
    View in: PubMed
    Score: 0.005
  279. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
    View in: PubMed
    Score: 0.005
  280. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.005
  281. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 2012 Apr 15; 118(8):2096-105.
    View in: PubMed
    Score: 0.005
  282. Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. Int J Cancer. 2012 Jun 01; 130(11):2740-2.
    View in: PubMed
    Score: 0.005
  283. Atopy is associated with asthma in adults living in rural and urban southwestern Nigeria. J Asthma. 2011 Nov; 48(9):894-900.
    View in: PubMed
    Score: 0.005
  284. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
    View in: PubMed
    Score: 0.005
  285. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
    View in: PubMed
    Score: 0.005
  286. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View in: PubMed
    Score: 0.005
  287. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702.
    View in: PubMed
    Score: 0.005
  288. A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet. 2011 Dec; 130(6):767-75.
    View in: PubMed
    Score: 0.005
  289. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011 Nov; 130(5):685-99.
    View in: PubMed
    Score: 0.005
  290. Differential allelic expression of c.1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR. Gene. 2011 Jul 15; 481(1):24-8.
    View in: PubMed
    Score: 0.005
  291. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.005
  292. Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Res Treat. 2011 Jun; 127(3):871-7.
    View in: PubMed
    Score: 0.005
  293. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1032-8.
    View in: PubMed
    Score: 0.005
  294. SNP discovery, expression and cis-regulatory variation in the UGT2B genes. Pharmacogenomics J. 2012 Aug; 12(4):287-96.
    View in: PubMed
    Score: 0.005
  295. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
    View in: PubMed
    Score: 0.005
  296. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.005
  297. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
    View in: PubMed
    Score: 0.005
  298. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
    View in: PubMed
    Score: 0.005
  299. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
    View in: PubMed
    Score: 0.005
  300. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet. 2010 Jul 22; 6(7):e1001029.
    View in: PubMed
    Score: 0.004
  301. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.004
  302. Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med. 2010 Jun; 63(6):1557-63.
    View in: PubMed
    Score: 0.004
  303. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.004
  304. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
    View in: PubMed
    Score: 0.004
  305. rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet. 2010 Mar; 197(2):193-4.
    View in: PubMed
    Score: 0.004
  306. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.004
  307. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.004
  308. Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15. Hum Mutat. 2010 Jan; 31(1):99-107.
    View in: PubMed
    Score: 0.004
  309. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S383-8.
    View in: PubMed
    Score: 0.004
  310. Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol. 2009 Oct 07; 54(19):5767-79.
    View in: PubMed
    Score: 0.004
  311. Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging. 2010 Jan; 28(1):16-21.
    View in: PubMed
    Score: 0.004
  312. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
    View in: PubMed
    Score: 0.004
  313. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
    View in: PubMed
    Score: 0.004
  314. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009; 11(5):R76.
    View in: PubMed
    Score: 0.004
  315. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.004
  316. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
    View in: PubMed
    Score: 0.004
  317. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
    View in: PubMed
    Score: 0.004
  318. Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet. 2008 Apr 15; 182(2):69-74.
    View in: PubMed
    Score: 0.004
  319. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
    View in: PubMed
    Score: 0.004
  320. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
    View in: PubMed
    Score: 0.004
  321. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
    View in: PubMed
    Score: 0.004
  322. Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging. 2008 Jun; 21(2):145-52.
    View in: PubMed
    Score: 0.004
  323. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
    View in: PubMed
    Score: 0.004
  324. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
    Score: 0.004
  325. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
    View in: PubMed
    Score: 0.004
  326. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
    View in: PubMed
    Score: 0.004
  327. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.004
  328. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
    View in: PubMed
    Score: 0.004
  329. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.004
  330. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.003
  331. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec; 3(12):e486.
    View in: PubMed
    Score: 0.003
  332. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
    View in: PubMed
    Score: 0.003
  333. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006 Jul; 21(7):779-85.
    View in: PubMed
    Score: 0.003
  334. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.003
  335. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006 Apr 27; 7:96.
    View in: PubMed
    Score: 0.003
  336. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
    View in: PubMed
    Score: 0.003
  337. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006; 8(2):R23.
    View in: PubMed
    Score: 0.003
  338. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006; 8(2):R15.
    View in: PubMed
    Score: 0.003
  339. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
    View in: PubMed
    Score: 0.003
  340. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb; 19(2):264-71.
    View in: PubMed
    Score: 0.003
  341. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.003
  342. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
    View in: PubMed
    Score: 0.003
  343. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
    View in: PubMed
    Score: 0.003
  344. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug; 16(6):667-74.
    View in: PubMed
    Score: 0.003
  345. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.003
  346. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
    View in: PubMed
    Score: 0.003
  347. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005 Feb 01; 23(4):685-93.
    View in: PubMed
    Score: 0.003
  348. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
    View in: PubMed
    Score: 0.003
  349. Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med. 2004 Jul; 52(1):193-6.
    View in: PubMed
    Score: 0.003
  350. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
    View in: PubMed
    Score: 0.003
  351. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
    View in: PubMed
    Score: 0.003
  352. Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys. 2004 Mar; 31(3):549-55.
    View in: PubMed
    Score: 0.003
  353. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.003
  354. The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
    View in: PubMed
    Score: 0.003
  355. EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 2003 Aug 07; 22(32):5070-81.
    View in: PubMed
    Score: 0.003
  356. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.003
  357. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
    View in: PubMed
    Score: 0.003
  358. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.
    View in: PubMed
    Score: 0.003
  359. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
    View in: PubMed
    Score: 0.003
  360. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
    View in: PubMed
    Score: 0.003
  361. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
    View in: PubMed
    Score: 0.002
  362. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.002
  363. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000 Oct; 6(10):3870-7.
    View in: PubMed
    Score: 0.002
  364. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.002
  365. Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer. 2000 Feb; 82(3):705-11.
    View in: PubMed
    Score: 0.002
  366. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999 Nov 27; 354(9193):1846-50.
    View in: PubMed
    Score: 0.002
  367. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 01; 91(17):1475-9.
    View in: PubMed
    Score: 0.002
  368. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher. 1999; 14(4):171-6.
    View in: PubMed
    Score: 0.002
  369. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
    Score: 0.002
  370. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6.
    View in: PubMed
    Score: 0.002
  371. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996 Dec; 2(12):1993-8.
    View in: PubMed
    Score: 0.002
  372. Analysis of tumor suppressor gene on human chromosome 9 in mouse x human somatic cell hybrids. Somat Cell Mol Genet. 1994 Sep; 20(5):391-400.
    View in: PubMed
    Score: 0.001
  373. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993 Mar 01; 53(5):1098-101.
    View in: PubMed
    Score: 0.001
  374. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer. 1992 Nov; 5(4):357-74.
    View in: PubMed
    Score: 0.001
  375. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.